William Blair Has Positive Outlook of VRTX FY2025 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at William Blair boosted their FY2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a report issued on Thursday, December 19th. William Blair analyst M. Minter now expects that the pharmaceutical company will post earnings of $16.65 per share for the year, up from their prior estimate of $16.61. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.83) per share.

Other research analysts have also issued research reports about the company. Raymond James restated a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Morgan Stanley boosted their price objective on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Oppenheimer lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $494.04.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $408.18 on Monday. The stock has a market cap of $105.12 billion, a PE ratio of -205.12 and a beta of 0.36. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a 50-day moving average price of $468.82 and a 200 day moving average price of $474.68. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period in the previous year, the firm earned $3.67 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% compared to the same quarter last year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Northwest Investment Counselors LLC purchased a new position in Vertex Pharmaceuticals during the 3rd quarter worth $25,000. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $27,000. Dunhill Financial LLC increased its holdings in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares in the last quarter. GHP Investment Advisors Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Finally, Stephens Consulting LLC acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter worth approximately $31,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.